Comparison the effect of sertraline and columipramine on premature ejaculatio
Phase 2
Recruiting
- Conditions
- Premature ejaculatuon.Premature ejaculationF52.4
- Registration Number
- IRCT20181117041682N3
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Age between 18-60 years
Possibility to have sex
Exclusion Criteria
The presence of genital ulcer infection
Systemic and neurological disorders
Severe psychiatric disorders
Use of drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration from moment of insertion to the moment of ejaculation,. Timepoint: at the start of treatment, 4,9,12 weeks after treatment. Method of measurement: Stopwatch.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sertraline and clomipramine efficacy in F52.4 premature ejaculation?
How does IRCT20181117041682N3 compare SSRIs and TCAs against standard-of-care for ejaculatory latency?
Are 5-HTTLPR polymorphisms or neurochemical biomarkers predictive of response to sertraline/clomipramine in PE?
What adverse event profiles differentiate sertraline from clomipramine in phase II PE trials?
What combination therapies or alternative SSRIs show promise for F52.4 premature ejaculation beyond IRCT20181117041682N3?